Halozyme Therapeutics EPS Estimates Down In Past Month

Analysts have become increasingly bearish on Halozyme Therapeutics in the month leading up to the company's first-quarter earnings announcement scheduled for Monday, May 12, 2014. The consensus analyst estimate has moved from a loss of 14 cents a share to the current prediction of a loss of 16 cents a share.The